MA31872B1 - Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers - Google Patents

Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers

Info

Publication number
MA31872B1
MA31872B1 MA32879A MA32879A MA31872B1 MA 31872 B1 MA31872 B1 MA 31872B1 MA 32879 A MA32879 A MA 32879A MA 32879 A MA32879 A MA 32879A MA 31872 B1 MA31872 B1 MA 31872B1
Authority
MA
Morocco
Prior art keywords
compounds
cancers
ksp
novel
inhibitors
Prior art date
Application number
MA32879A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Paul A Renhowe
Annette Olga Walter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31872(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31872B1 publication Critical patent/MA31872B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA32879A 2007-12-14 2010-05-31 Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers MA31872B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14
PCT/EP2008/067412 WO2009077448A1 (en) 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics

Publications (1)

Publication Number Publication Date
MA31872B1 true MA31872B1 (fr) 2010-11-01

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32879A MA31872B1 (fr) 2007-12-14 2010-05-31 Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers

Country Status (30)

Country Link
US (2) US8252832B2 (enExample)
EP (1) EP2229170B1 (enExample)
JP (1) JP5501976B2 (enExample)
KR (1) KR20100098394A (enExample)
CN (1) CN101939005B (enExample)
AR (1) AR069676A1 (enExample)
AU (1) AU2008337570B2 (enExample)
BR (1) BRPI0821248A2 (enExample)
CA (1) CA2708822A1 (enExample)
CL (1) CL2008003707A1 (enExample)
CO (1) CO6290651A2 (enExample)
CR (1) CR11412A (enExample)
DO (1) DOP2010000175A (enExample)
EA (1) EA018014B1 (enExample)
EC (1) ECSP10010248A (enExample)
ES (1) ES2459442T3 (enExample)
GE (1) GEP20125647B (enExample)
GT (1) GT201000172A (enExample)
IL (1) IL205831A0 (enExample)
MA (1) MA31872B1 (enExample)
MY (1) MY150214A (enExample)
NI (1) NI201000091A (enExample)
NZ (1) NZ585142A (enExample)
PA (1) PA8807801A1 (enExample)
PE (1) PE20091451A1 (enExample)
SM (1) SMP201000095B (enExample)
TN (1) TN2010000204A1 (enExample)
TW (1) TW200930704A (enExample)
UY (1) UY31532A1 (enExample)
WO (1) WO2009077448A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
EP2558452A2 (en) * 2010-04-15 2013-02-20 Novartis AG Oxazole and thiazole compounds as ksp inhibitors
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
CA2990076A1 (en) * 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
RU2761390C2 (ru) 2016-12-21 2021-12-07 Байер Фарма Акциенгезельшафт Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2409345T3 (es) * 2004-06-18 2013-06-26 Novartis Ag Derivados y compuestos relacionados de N-(1- (1-bencil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil)benzamida como inhibidores de la proteína quinesina de huso (KSP) para el tratamiento del cáncer
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
NZ577727A (en) 2007-01-05 2012-03-30 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)

Also Published As

Publication number Publication date
MY150214A (en) 2013-12-13
CA2708822A1 (en) 2009-06-25
GT201000172A (es) 2012-04-30
BRPI0821248A2 (pt) 2015-06-16
SMAP201000095A (it) 2010-09-10
US8252832B2 (en) 2012-08-28
CN101939005A (zh) 2011-01-05
PA8807801A1 (es) 2009-07-23
NI201000091A (es) 2011-03-15
CO6290651A2 (es) 2011-06-20
ES2459442T3 (es) 2014-05-09
AU2008337570B2 (en) 2012-04-05
EA201000900A1 (ru) 2011-02-28
CL2008003707A1 (es) 2009-06-05
ECSP10010248A (es) 2010-07-30
TN2010000204A1 (en) 2011-11-11
US8664256B2 (en) 2014-03-04
EA018014B1 (ru) 2013-04-30
EP2229170B1 (en) 2014-01-22
SMP201000095B (it) 2011-09-09
US20090239922A1 (en) 2009-09-24
CN101939005B (zh) 2015-12-16
US20130012560A1 (en) 2013-01-10
KR20100098394A (ko) 2010-09-06
UY31532A1 (es) 2009-08-03
EP2229170A1 (en) 2010-09-22
GEP20125647B (en) 2012-09-25
CR11412A (es) 2010-06-30
TW200930704A (en) 2009-07-16
AR069676A1 (es) 2010-02-10
PE20091451A1 (es) 2009-10-19
JP2011506402A (ja) 2011-03-03
JP5501976B2 (ja) 2014-05-28
WO2009077448A1 (en) 2009-06-25
NZ585142A (en) 2012-03-30
DOP2010000175A (es) 2010-06-30
IL205831A0 (en) 2010-11-30
AU2008337570A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
MA31872B1 (fr) Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers
Shih Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27937A1 (fr) Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA31001B1 (fr) Quinazolines destines a l'inhibition de pdk
MA34909B1 (fr) Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
TN2009000033A1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
Crott et al. Accumulation of mitochondrial DNA deletions is age, tissue and folate-dependent in rats
WO2023122782A3 (en) Indoles, indazoles, and related analogs for inhibiting yap/taz-tead
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
WO2012171015A3 (en) Therapeutic combination for cancer treatment
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
TW200512198A (en) 5-arylpyrimidines as anticancer agents
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
Gasparetto et al. Selinexor in combination with carfilzomib and dexamethasone, all once weekly (SKd), for patients with relapsed/refractory multiple myeloma
MX340669B (es) Formas farmaceuticas para compuestos debilmente ionizables.
FR2870539A1 (fr) Nouvelles methodes et medicaments
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
ATE454889T1 (de) Arzneimittel zur behandlung von sarkoglykanopathien
Im et al. Trial in progress: a phase 3 study of itacitinib or placebo in combination with corticosteroids as initial treatment for chronic graft-versus-host disease (GRAVITAS-309)